Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Other financing activities (2020 - 2025)

SAB Biotherapeutics' Other financing activities history spans 6 years, with the latest figure at $4881.0 for Q3 2025.

  • For Q3 2025, Other financing activities changed N/A year-over-year to $4881.0; the TTM value through Sep 2025 reached $29795.0, changed N/A, while the annual FY2025 figure was $11205.0, 45.1% down from the prior year.
  • Other financing activities reached $4881.0 in Q3 2025 per SABSW's latest filing, up from $2072.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $349115.0 in Q1 2021 to a low of -$201477.0 in Q4 2021.
  • Average Other financing activities over 5 years is $11540.6, with a median of $3655.5 recorded in 2023.
  • Peak YoY movement for Other financing activities: tumbled 351.43% in 2021, then surged 980.0% in 2024.
  • A 5-year view of Other financing activities shows it stood at -$201477.0 in 2021, then skyrocketed by 134.32% to $69141.0 in 2022, then tumbled by 96.49% to $2430.0 in 2023, then surged by 740.0% to $20412.0 in 2024, then tumbled by 76.09% to $4881.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Other financing activities are $4881.0 (Q3 2025), $2072.0 (Q1 2025), and $20412.0 (Q1 2024).